<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02772887</url>
  </required_header>
  <id_info>
    <org_study_id>PRO15090627</org_study_id>
    <nct_id>NCT02772887</nct_id>
  </id_info>
  <brief_title>Nutraceutical Citrulline in Pregnancy</brief_title>
  <official_title>Phase 1 Trial Citrulline and Type 2 Diabetes in Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if oral of L-citrulline (3 grams/day) for 3 weeks&#xD;
      provided in mid-pregnancy to pregnant women with type 2 diabetes will increase the plasma&#xD;
      L-arginine/ADMA ratio, lower maternal blood pressure and increase maternal levels of&#xD;
      placental growth factor (PlGF).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The pregnancy-specific syndrome preeclampsia is a leading cause of maternal and fetal&#xD;
      morbidity and mortality. The underlying cause of preeclampsia is unknown, however several&#xD;
      pre-existing maternal conditions are associated with an increased risk of preeclampsia&#xD;
      including: diabetes, hypertension, renal dysfunction, obesity and history of preeclampsia.&#xD;
      Specifically, the risk of preeclampsia is five times greater in women with diabetes.&#xD;
&#xD;
      Several lines of evidence indicate that endothelial dysfunction is a central feature of the&#xD;
      pathophysiology of preeclampsia. Asymmetric dimethylarginine (ADMA) is a methylated&#xD;
      metabolite of the amino acid L-arginine and an endogenous inhibitor of nitric oxide synthase&#xD;
      (NOS). High concentrations of ADMA contribute to endothelial dysfunction and ADMA inhibits&#xD;
      angiogenesis and arteriogenesis, activities important in pregnancy and deficient in&#xD;
      preeclampsia. ADMA concentrations are higher early in pregnancy among women who later develop&#xD;
      preeclampsia. This protocol describes a randomized placebo-controlled trial of L-citrulline&#xD;
      in 40 pregnant women with type 2 diabetes from approximately sixteen to nineteen weeks&#xD;
      gestation, to determine whether L-citrulline supplementation increases the plasma&#xD;
      L-arginine/ADMA ratio, lowers maternal blood pressure and increases a circulating marker of&#xD;
      placental function (placental growth factor PLGF).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inability to successfully recruit study participants&#xD;
  </why_stopped>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Actual">May 2019</completion_date>
  <primary_completion_date type="Actual">May 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>approximately 20 weeks</time_frame>
    <description>research measure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Placental growth factor (PlGF)</measure>
    <time_frame>approximately 20 weeks</time_frame>
    <description>quantified by ELISA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Citrulline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral L-citrulline, 3 grams once per day for 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, 3 grams once per day for 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L-Citrulline</intervention_name>
    <description>amino acid supplement</description>
    <arm_group_label>Citrulline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Singleton pregnancy&#xD;
&#xD;
          -  Type 2 diabetes with hemoglobin A1c &lt;8&#xD;
&#xD;
          -  Gestational age at randomization between 14 and 16 weeks based on clinical information&#xD;
&#xD;
          -  Maternal age between 14 and 40 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic hypertension&#xD;
&#xD;
          -  Major fetal anomaly&#xD;
&#xD;
          -  Fetal demise&#xD;
&#xD;
          -  Planned termination of the pregnancy&#xD;
&#xD;
          -  Collagen vascular disease (autoimmune disease) on medication&#xD;
&#xD;
          -  Renal disease&#xD;
&#xD;
          -  Epilepsy or other seizure disorder&#xD;
&#xD;
          -  Active or chronic liver disease&#xD;
&#xD;
          -  Heart disease, known illicit drug or alcohol abuse during current pregnancy&#xD;
&#xD;
          -  Already taking L-citrulline as a supplement (1gram/day or more)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Magee-Womens Hospital of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>February 12, 2016</study_first_submitted>
  <study_first_submitted_qc>May 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2016</study_first_posted>
  <last_update_submitted>May 28, 2019</last_update_submitted>
  <last_update_submitted_qc>May 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Robert Powers</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>pregnancy</keyword>
  <keyword>type 2 diabetes</keyword>
  <keyword>asymmetric dimethylarginine</keyword>
  <keyword>L-arginine</keyword>
  <keyword>L-citrulline</keyword>
  <keyword>placental growth factor (PlGF)</keyword>
  <keyword>blood pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

